Are there Therapeutic Interventions for RTK-Related Toxicity?
Yes, there are therapeutic strategies to address RTK-related toxicity. Small molecule inhibitors and monoclonal antibodies have been developed to specifically target overactive RTKs in cancer therapy. In cases where RTK activity is impaired, ligand supplementation or gene therapy may be considered to restore normal function. However, these interventions must be approached with caution to avoid off-target effects and further toxicity.
